ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (01541.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 3.38

From 52W high−81.09%

Volume227200.00

Market capHKD 1.30B

P/E (TTM)—

P/S (TTM)7.3x

Div yield—

Key dataSep 18, 2026

Open

HKD 3.38

From 52W high

−81.09%

Volume

227200.00

Market cap

HKD 1.30B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.7x

P/E (TTM)

—

RSI (14)

40.4

MomentumView details →

1D Return

−1.56%

YTD Return

−45.97%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−2.7x

EV/Sales

3.5x

P/S (TTM)

7.3x

P/B (TTM)

1.8x

ProfitabilityView details →

Gross Margin

94.57%

Net Margin

−151.13%

EBITDA Margin

−128.05%

ROE (TTM)

−36.60%

ROA (TTM)

−22.24%

Asset Turnover

0.14x

GrowthView details →

Revenue YoY

+23.40%

EPS YoY

+32.05%

FCF YoY

+48.07%

Revenue CAGR 3Y

+197.82%

EPS CAGR 3Y

+39.29%

EBITDA YoY

+35.48%

MomentumView details →

1D Return

−1.56%

YTD Return

−45.97%

1Y Return

−73.99%

RSI (14)

40.4

vs 50D SMA

−7.04%

vs 200D SMA

−29.06%

Capital & dividendView details →

Debt/Equity

0.58x

Current Ratio

2.66x

Quick Ratio

2.66x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−HKD 0.44

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

274.41M

Net Income (TTM)

−531.76M

Op. CF (TTM)

−208.55M

Next earningsMar 30, 2027 →

Latest newsMore news →

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the first patient has been dosed in its Phase II clinical trial of IMM2510 combined with IMM27M for first-line treatment of advanced hepatocellular carcinoma.24d ago

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced its interim results for the six months ended June 30, with revenue of 25.42 million RMB, down 33.1% year-on-year, net loss widening to 164 million RMB, loss per share of 0.38 RMB, and no dividend.25d ago

Similar companies

Omeros CorporationOMER Immatics N.V.IMTX ORIC Pharmaceuticals, Inc.ORIC MeiraGTx Holdings plcMGTX Vor Biopharma Inc.VOR NewAmsterdam Pharma Company N.V.NAMSW Find similar companies →

Latest newsMore news →

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the first patient has been dosed in its Phase II clinical trial of IMM2510 combined with IMM27M for first-line treatment of advanced hepatocellular carcinoma.24d ago ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced its interim results for the six months ended June 30, with revenue of 25.42 million RMB, down 33.1% year-on-year, net loss widening to 164 million RMB, loss per share of 0.38 RMB, and no dividend.25d ago